复星医药(600196.SH)：预计Gland Pharma股份将于印度标准时间11月20日在孟买证交所及印度证交所开始买卖
格隆汇 11 月 13日丨复星医药(600196.SH)公布，Gland Pharma已于印度标准时间2020年11月12日向印度的公司注册处(位于印度特伦甘纳邦的海得拉巴，“公司注册处”)递交日期为2020年11月12日之正式招股书(其中包括股份发行价格、募资规模等详情，“招股书”)，并于印度标准时间2020年11月13日向Securities and Exchange Board of India(即印度证券交易委员会，“SEBI”)、孟买证券交易所(“孟买证交所”)及印度国家证券交易所(“印度证交所”)递交招股书。
根据招股书，待确定配股基准后，此次Gland Pharma境外上市将公开发售共计4319.6968万股股份，其中：(1)以新股发行方式公开发售833.3333万股股份(“新股发行”)，(2)以现有股东发售股份(即存量股转让，下同)方式公开发售3486.3635万股股份(包括公司控股子公司Fosun Pharma Industrial Pte. Ltd.出售1936.8686万股股份、其他现有股东出售合计1549.4949万股股份)。上述股份的最终发售价格均为1500印度卢比/股。
预计Gland Pharma境外上市公开发售的股份将于印度标准时间2020年11月19日(星期四)分配至承配人账户。如获孟买证交所及印度证交所最终上市及交易核准，预计Gland Pharma股份将于印度标准时间2020年11月20日(星期五)在孟买证交所及印度证交所开始买卖。
此次Gland Pharma通过新股发行预计将募得款项(未扣除发行费用)合计125亿印度卢比(按2020年11月12日汇率中间价0.0889预估折合人民币约11.11亿元)。新股发行所得款项净额(扣除发行费用后)将由Gland Pharma用于日常营运、资本支出等。此次Gland Pharma境外上市有利于Gland Pharma进一步优化公司治理及资本结构，保持和扩大其行业领先优势，实现持续发展。
于此次Gland Pharma境外上市中，公司控股子公司Fosun Pharma Industrial Pte. Ltd.将出售Gland Pharma 1936.8686万股股份，所得款项为290.53亿印度卢比(税前且未扣除发行费用，按2020年11月12日汇率中间价0.0889预估折合人民币约25.84亿元)。此次出售款项将由集团用于偿还带息债务及日常运营。
紧随Gland Pharma境外上市(包括新股发行及存量股转让)完成，公司(通过控股子公司)对Gland Pharma的持股比例将由74%降至58.36%，Gland Pharma仍为公司控股子公司；此次出售系转让控股子公司部分股权，股权出售所得不计入投资收益，但将增厚本集团归属母公司净资产。实际财务影响以审计结果为准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
